Archit Organosys FY26 Results: Net profit rises 59% YoY

ScanX News Archit Organosys FY26 Results: Net profit rises 59% YoY 1 min read | Published on 08 Sept 2026, 01:00 AM | Updated on 08 Sept 2026, 01:00 AM Reviewed by Add as a preferred source on Google *this image is generated using AI for illustrative purposes only. Archit Organosys reported a 59% year-on-year increase in net profit for FY26, reaching ₹803.21 lakh. The chemical manufacturer saw total income grow by 11.77% to ₹14,383.71 lakh, reflecting improved operational performance and cost management. The Board of Directors has recommended a final dividend of ₹1 per equity share, representing a 10% payout on the face value of ₹10. This marks a step-up from the previous year's dividend of ₹0.50 per share. Financial Performance Revenue from operations stood at ₹14,095.25 lakh for the fiscal year ended March 31, 2026, compared to ₹12,559.92 lakh in FY25. The company managed to expand its profit before tax (PBT) to ₹1,099.25 lakh, up from ₹753.89 lakh in the prior year. Metric FY26 FY25 Change Total Income ₹14,383.71 lakh ₹12,869.20 lakh +11.77% PBT ₹1,099.25 lakh ₹753.89 lakh +45.80% Net Profit ₹803.21 lakh ₹505.11 lakh +59.02% Operating costs rose to ₹13,055.64 lakh from ₹11,857.33 lakh, while financial expenses declined slightly to ₹228.82 lakh from ₹257.98 lakh. What the Numbers Show The divergence between revenue growth and profit expansion indicates improved operating leverage. While top-line growth was modest at 11.77%, the bottom line accelerated significantly due to a combination of lower financial costs and controlled operational expenses relative to income. The effective tax rate decreased to 26.93% from 33.00% in the previous year, further supporting the net profit margin expansion. Corporate Governance and Strategy The company's paid-up equity share capital remained unchanged at ₹20.52 crore. During the year, there were changes in key managerial personnel, with Anilkumar G. Patel appointed as Chief Financial Officer and Chirag Chouhan as Company Secretary. The Board highlighted confidence in future performance, citing opportunities in the specialty chemicals boom and expanding export markets. The company continues to focus on technology absorption and energy conservation to maintain competitive advantage in the chemical manufacturing sector. Historical Stock Returns for Archit Organosys 1 Day 5 Days 1 Month 6 Months 1 Year 5 Years + 4. 36 % + 1. 89 % + 8. 14 % + 66. 32 % + 37. 28 % 0.0% How will the newly appointed CFO, Anilkumar G. Patel, influence Archit Organosys's capital allocation strategy and debt management in the coming fiscal year? fuzz it Which specific export markets or specialty chemical segments are driving the company's growth, and what regulatory or geopolitical risks could impact these channels? fuzz it Can Archit Organosys sustain its improved operating leverage and net profit margins given the rising input costs typical in the chemical manufacturing sector? fuzz it ScanX News Archit Organosys FY26 Results: Net profit rises 59% YoY 1 min read | Published on 27 Aug 2026, 08:55 PM | Updated on 27 Aug 2026, 08:55 PM Reviewed by Add as a preferred source on Google *this image is generated using AI for illustrative purposes only. Archit Organosys Limited has scheduled a Board of Directors meeting for September 3, 2026. The agenda includes evaluating proposals to raise capital through equity shares or other permissible securities. The company disclosed the meeting under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Board may consider issuing equity shares, share warrants, or other equity-based instruments through a preferential issue on a private placement basis. Any such issuance is subject to receipt of relevant approvals as may be required by the Board and regulatory authorities. The company did not disclose the specific amount or purpose of the proposed fundraising in the intimation. Trading Window Closure In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window has been closed for Promoters, Directors, Senior Managerial Personnel, along with their immediate relatives and other connected persons. The window will reopen after the expiry of 48 hours from the time the event becomes generally available. This restriction applies until the details of the board meeting outcomes are made public. Corporate Governance Kandarp Amin, Chairman and Whole-time Director, signed the intimation letter dated August 27, 2026. The communication was addressed to BSE Limited, requesting the exchange to take the information on record. Historical Stock Returns for Archit Organosys 1 Day 5 Days 1 Month 6 Months 1 Year 5 Years + 4. 36 % + 1. 89 % + 8. 14 % + 66. 32 % + 37. 28 % 0.0% What specific strategic initiatives or operational expansions is Archit Organosys likely funding with this proposed equity raise? fuzz it How might the dilution from a preferential issue impact the current share price and promoter holding percentages? fuzz it Which institutional investors or strategic partners are most likely to participate in this private placement given the company's sector focus? fuzz it view all